Abigale Lo

Buyers who stock hormone therapy products know that dose flexibility matters. Not every patient needs a standard-strength regimen, and pharmacies that can offer a lower-dose option serve prescribers and patients better. Abigale Lo from Xiromed fills that gap. This low-dose combined hormone replacement therapy tablet pairs Estradiol Hemihydrate with Norethisterone Acetate in a reduced-strength formulation, giving your catalog a practical companion to standard-dose alternatives.

Product Overview

Abigale Lo is a continuous combined hormone replacement therapy (HRT) tablet supplied at a strength of 0.5 mg / 0.1 mg. Each carton contains three blister cards of 28 tablets, totaling 84 tablets per pack. This 3 x 28 layout maps neatly to continuous treatment cycles, so patients can complete a full therapy period without an early refill, and pharmacy teams can maintain a clean reorder rhythm.

The reduced strength is the defining feature here. Where a standard-dose product suits patients who need fuller hormonal replacement, Abigale Lo addresses the demand for a gentler starting point or a maintenance option. That distinction makes it a genuine addition to your shelf rather than a duplicate line, and it helps prescribers tailor therapy to individual patient profiles.

Abigale Lo carries NDC 70700-303-85. Wholesalers and distributors can verify this code against inventory systems before ordering, which cuts down on mismatched shipments and speeds up procurement. Every tablet supplies a fixed dose of both active ingredients, removing the variability that comes with separate-component approaches.

Active Ingredients and Their Roles

A combination HRT product works because its two components complement one another. Abigale Lo pairs a low dose of estrogen with a low dose of progestogen, and each serves a defined purpose within the regimen.

Estradiol Hemihydrate (0.5 mg) is the estrogen component. As natural estrogen production tapers, patients may experience symptoms linked to estrogen deficiency. At 0.5 mg, Abigale Lo provides a lower estrogen dose than standard-strength options, which supports prescribers who want to begin therapy conservatively or keep patients on a reduced level. This measured amount forms the primary therapeutic driver of the formulation.

Norethisterone Acetate (0.1 mg) is the progestogen component. In women with an intact uterus, estrogen given on its own can affect the endometrium, the lining of the uterus. Norethisterone Acetate is included to help protect that lining throughout estrogen therapy. The 0.1 mg dose reflects the balanced, lower-strength design of this product and follows established clinical practice for continuous combined HRT.

Delivering both hormones in one daily oral tablet keeps the regimen simple. Patients manage a single product rather than juggling separate items, and dispensers handle one SKU instead of coordinating multiple components. That simplicity carries real value for adherence and for day-to-day pharmacy operations.

Indications and Use

Abigale Lo sits within the combined hormone replacement therapy category and is intended for use under the direction of a qualified healthcare professional. Products of this kind are commonly prescribed for:

• Relief of symptoms associated with estrogen deficiency, particularly where a lower-dose approach is preferred
• Continuous combined hormone replacement therapy in appropriate patients with an intact uterus

Because Abigale Lo is a low-dose formulation, it may suit prescribers who favor starting patients at a reduced strength or maintaining them there. All prescribing decisions, dosing, patient selection, and treatment duration should follow the approved product labeling and the clinical judgment of the treating physician. This description is written for licensed professionals and authorized trade partners and does not replace the full prescribing information.

Pack Configuration and Key Details

Accurate specifications keep procurement smooth. Here is what to confirm before adding Abigale Lo to your catalog:

• Strength: 0.5 mg / 0.1 mg per tablet
• Pack size: 3 x 28 tablets (84 tablets total)
• NDC: 70700-303-85
• Dosage form: Oral tablet
• Category: Low-dose continuous combined hormone replacement therapy

The three-card structure supports a full continuous therapy schedule, so patients move through treatment without a mid-cycle gap. For pharmacy operations, that translates to fewer partial-supply headaches and a predictable reorder pattern.

Why Source Through Xiromed

Consistent supply matters as much as the product itself. Xiromed manufactures its portfolio to meet stringent regulatory standards, and Abigale Lo holds to the same benchmark. Each batch is produced with consistency in mind, so your supply chain receives a product that performs the same way from one order to the next.

Sourcing Abigale Lo directly through Xiromed gives buyers verified specifications, a confirmed NDC for precise matching, and a supply relationship built around the needs of pharmacies and distributors. Stocking both a standard-dose and a low-dose option lets you serve a wider range of prescriber preferences from a single manufacturer.

If you are broadening your hormone therapy category or securing a steady low-dose option, Abigale Lo is a clear-cut choice. To order or request additional product information, connect with the Xiromed team and reference NDC 70700-303-85 to confirm the exact 0.5 mg / 0.1 mg, 3 x 28 configuration for your inventory.

This information is intended for licensed healthcare professionals, pharmacies, and authorized distributors. Abigale Lo is a prescription product and should be used only as directed by a qualified healthcare provider in accordance with the approved product labeling. Product availability, specifications, and regulatory status may vary by region. Refer to the full prescribing information before dispensing.